Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Okata, Takuya ^a   Toyoda, Kazunori ^a   Okamoto, Akira ^a   Miyata, Toshiyuki ^a   Nagatsuka, Kazuyuki ^a   Minematsu, Kazuo ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FACTOR XA ANTIBODY; PROTEIN ANTIBODY; RIVAROXABAN; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYSPHAGIA; FACTORIAL ANALYSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; JAPAN; JAPANESE (PEOPLE); LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; PROTHROMBIN TIME; STEADY STATE; STROKE PATIENT; TABLET FORMULATION; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BLOOD CLOTTING; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; ETHNOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; STROKE; THROMBOEMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RIVAROXABAN; STROKE; THROMBOEMBOLISM;

EID: 84913554648     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113641     Document Type: Article

References (19)

1. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 146: 857-67.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 27: 1979-2030.
3. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, et al. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 3: 514-21.
4. Kaneko M, Tanigawa T, Hashizume K, Kajikawa M, Tajiri M, et al. (2013) Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet. 28: 321-31.
5. Hori M, Matsumoto M, Tanahashi N, Momomura S, J-ROCKET AF study investigators, et al. (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study -. Circ J. 76: 2104-11.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365: 883-91.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361: 1139-51.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al. (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 369: 2093-104.
9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 365: 981-92.
10. Xarelto [package insert]. Bayer Schering Pharma AG; 2013.
11. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, et al. (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 103: 815-25.
12. Samama MM, Contant G, Spiro TE, Perzborn E, Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories, et al. (2012) Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 107: 379-87.
13. Lange N, Laird NM (1989) The effects of Covariance Structure on Variance Estimation in Balanced Growth-Curve Models. J Am Stat Assoc. 84: 241-7.
14. Toyoda K (2012) The cerebro-renal interaction in stroke neurology. Neurology. 78: 1898-9.
15. Toyoda K (2013) Cerebrorenal interaction and stroke. Contrib Nephrol. 179: 1-6.
16. Moore KT, Vaidyanathan S, Damaraju CV, Fields LE (2012) The relative bioavailability of single-dose rivaroxaban, a novel oral anticoagulant and a selective direct factor Xa inhibitor, administered orally (as a whole or crushed tablet) and via nasogastric tube (as a crushed tablet suspension). ACCP Annual Meeting [Abstract].
17. Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, et al. (2013) Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 28: 59-70.
18. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, et al. (2002) First experience with direct Factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamics evaluation. Circulation. 105: 2385-91.
19. Samama MM, Gerotziafas GT, Elalamy I, Horellou MH, Conard J (2002) Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 32: 218-24.